ABOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Acumen Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was $300.97 Mil.
During the past 12 months, Acumen Pharmaceuticals's average Total Assets Growth Rate was 2.10% per year. During the past 3 years, the average Total Assets Growth Rate was 367.50% per year.
During the past 5 years, Acumen Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 367.50%. The lowest was 191.00%. And the median was 279.25%.
Total Assets is connected with ROA %. Acumen Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -19.47%. Total Assets is also linked to Revenue through Asset Turnover. Acumen Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.
The historical data trend for Acumen Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acumen Pharmaceuticals Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Total Assets | 7.32 | 44.43 | 230.33 | 196.59 | 310.13 |
Acumen Pharmaceuticals Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Assets | Get a 7-Day Free Trial | 187.86 | 177.41 | 286.37 | 310.13 | 300.97 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Acumen Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (A: Dec. 2023 ) | + | Total Liabilities (A: Dec. 2023 ) |
= | 266.973 | + | 43.152 | |
= | 310.13 |
Acumen Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as
Total Assets | = | Total Equity (Q: Mar. 2024 ) | + | Total Liabilities (Q: Mar. 2024 ) |
= | 262.034 | + | 38.933 | |
= | 300.97 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acumen Pharmaceuticals (NAS:ABOS) Total Assets Explanation
Total Assets is connected with ROA %.
Acumen Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is
ROA % | = | Net Income (Q: Mar. 2024 ) | / | ( (Total Assets (Q: Dec. 2023 ) | + | Total Assets (Q: Mar. 2024 )) | / count ) |
= | -59.492 | / | ( (310.125 | + | 300.967) | / 2 ) | |
= | -59.492 | / | 305.546 | ||||
= | -19.47 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Acumen Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is
Asset Turnover | ||||||
= | Revenue (Q: Mar. 2024 ) | / | ( (Total Assets (Q: Dec. 2023 ) | + | Total Assets (Q: Mar. 2024 )) | / count ) |
= | 0 | / | ( (310.125 | + | 300.967) | / 2 ) |
= | 0 | / | 305.546 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Acumen Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Joseph Oconnell | director, officer: President and CEO | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Derek M Meisner | officer: Chief Legal Office & Corp Sec | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
Eric Siemers | officer: Chief Medical Officer | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Russell Barton | officer: Chief Operating Officer | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Matt Zuga | officer: Chief Financial Officer | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Jeffrey L. Ives | director | C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Derrell Porter | director | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080 |
Kimberlee C Drapkin | director | PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Paul B Manning | 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Stalfort John A Iii | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Robert D. Hardie | 10 percent owner | 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903 |
Nathan B Fountain | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Sands Capital Global Venture Fund Ii, L.p. | 10 percent owner | C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209 |
Sands Capital Life Sciences Pulse Fund, Llc | 10 percent owner | C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209 |
From GuruFocus
By Value_Insider Value_Insider • 10-24-2022
By sperokesalga sperokesalga • 05-02-2023
By sperokesalga sperokesalga • 06-13-2023
By GlobeNewswire • 07-19-2023
By Marketwired • 11-02-2023
By PRNewswire • 07-17-2023
By Marketwired • 07-19-2023
By Value_Insider Value_Insider • 11-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.